Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FLUTAMIDE
Stada Arzneimittel AG
250 Milligram
Tablets
1999-06-25
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Flutamid Stada 250 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Flutamide 250 mg For excipients, see 6.1. 3 PHARMACEUTICAL FORM Tablet Pale yellow round tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of advanced prostatic carcinoma in which suppression of testosterone effects is indicated. Flutamid Stada may be used as initial treatment in combination with LHRH agonists or as adjunctive therapy in patients, already receiving LHRH agonist therapy. Flutamid Stada may also be used in surgically castrated patients. 4.2 POSOLOGY AND METHOD OF ADMINSTRATION _Adults and Elderly: _One tablet three times daily. The tablets should be taken preferably after meals. When Flutamid Stada tablets are used as initial treatment with an LHRH agonist, a reduction in severity of the flare reaction may be achieved if treatment with Flutamid Stada is initiated before the LHRH agonist. Consequently, it is recommended that treatment with Flutamid Stada should commence at least 3 days before the LHRH agonist. In patients with impaired liver function, long-term treatment with flutamide should only be initiated after careful assessment of the individual benefits and risks. Flutamid Stada should be administered with caution in patients with impaired renal function. 4.3 CONTRAINDICATIONS Flutamid Stada is contraindicated in patients who are hypersensitive to flutamide or any component of the product. For patients with severe liver impairment (Child Pugh C) the use of flutamide is also contraindicated. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE In patients with pre-existing liver dysfunction the hazard of flutamide-induced hepatic injury may be increased. Therefore, in these patients long-term treatment Read the complete document